Mirati Therapeutics Stock News

Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.

Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - CEO James Christensen

Full results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib in patients with pre-treated non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation Lat

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl

Mirati has a PDUFA on December 14. Lumakras is already approved conditionally, with confirmatory data this year.

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.

Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trad

SAN DIEGO, March 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Cowen Healthcare Conference, which will be webcast on March 9 at 10:30 a.m. P.T. / 1:30 p.m. E.T. David Meek,…

Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 3 0 0

Within the last quarter, Mirati Therapeutics (NASDAQ: MRTX ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 3 0 0 Last 30D 1 0 1 0 0 1M Ago 0 0 2 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Mirati Therapeutics has an average price target of $137.25 with a high of $150.00 and a low of $118.00. Below is a summary of how these 4 analysts rated Mirati Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts … Full story available on Benzinga.com

Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.

Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.